Richard A. Miller

Dr. Richard Miller currently serves as co-founder, president and chief executive officer of Corvus Pharmaceuticals, a public biotechnology company. He co-founded and was chief executive officer of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, vice president and director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude and completed residency and fellowship programs in internal medicine and medical oncology at Stanford University Medical Center. He is a board-certified oncologist and is currently adjunct clinical professor of medicine (oncology) at Stanford University Medical Center.